Every red-cell result you release, from the blood film and reticulocyte count to bilirubin, haptoglobin, and the iron profile, reflects one stage of a single life cycle. The cycle begins with hematopoietic stem and progenitor cells in marrow, passes through recognizable erythroblast stages, and ends when macrophages clear aged or damaged erythrocytes. A change at any stage can appear in the marrow, the peripheral blood film, or those results.1
Hematopoietic sites and marrow organization
Human blood production develops in overlapping waves. Early embryonic erythroid cells arise in the yolk sac. Definitive hematopoietic stem cells emerge from hemogenic endothelium, the vessel lining that gives rise to blood cells, in intraembryonic sites that include the aorta-gonad-mesonephros region, then expand chiefly in the fetal liver. Bone marrow becomes the main hematopoietic organ before birth and remains so through adult life.2
Scroll sideways to see all columns
| Developmental period | Main site or structure | Hematologic result |
|---|---|---|
| Early embryo | Yolk sac | Primitive erythroid cells and early myeloid and megakaryocytic cells |
| Early embryo | Hemogenic endothelium, including the aorta-gonad-mesonephros region | Long-lived hematopoietic stem cells that support definitive blood production |
| Fetal life, especially midgestation | Liver, with contributions from placenta, spleen, and thymus | Expansion and differentiation of definitive stem and progenitor cells |
| Mid-to-late fetal life through adulthood | Bone marrow | Normal production of erythrocytes, granulocytes, monocytes, lymphoid cells, and platelets |
In adults, hematopoietically active red marrow is concentrated in the vertebrae, pelvis, ribs, sternum, skull, scapulae, and proximal humeri and femora. Yellow marrow contains more adipose tissue and less hematopoietic activity. Severe, sustained demand can recruit additional marrow and drive extramedullary hematopoiesis in the liver or spleen.1
Red marrow consists of hematopoietic cords between vascular sinuses. Developing erythroblasts form erythroblastic islands around macrophages that support maturation, handle extruded nuclei, and help supply iron. Megakaryocytes lie next to sinusoidal endothelium and extend platelet-forming processes toward the blood. Granulocytic precursors mature deeper in the cords. Endothelial cells, mesenchymal stromal cells, macrophages, osteolineage cells, extracellular matrix, cytokines, and adhesion molecules together form the marrow niche that regulates stem-cell maintenance and lineage output.1,3
Stem cells, progenitors, and growth factors
A hematopoietic stem cell can self-renew and produce every mature blood lineage. The classical laboratory map places multipotent progenitors below the stem cell, followed by common myeloid and lymphoid branches and then lineage-restricted progenitors. Colony assays supplied names such as CFU-GEMM (the granulocyte, erythroid, macrophage, and megakaryocyte colony-forming unit), BFU-E, CFU-E, CFU-GM, and CFU-Meg. These names describe growth behavior under defined culture conditions. Single-cell studies show gradual lineage priming and heterogeneous progenitor populations, so read the branching map as a teaching model of a continuous process.2,4
Scroll sideways to see all columns
| Progenitor or factor | Main relationship |
|---|---|
| BFU-E | Early erythroid colony-forming progenitor; human colony assays commonly use stem cell factor with erythropoietin |
| CFU-E | Late erythroid progenitor with strong dependence on erythropoietin |
| CFU-Meg | Megakaryocytic progenitor |
| CFU-GM, CFU-G, CFU-M | Granulocyte-monocyte, granulocyte, and monocyte colony-forming progenitors |
| Stem cell factor and FLT3 ligand | Support early stem and progenitor survival and expansion |
| Erythropoietin | Promotes survival, proliferation, and maturation of committed erythroid cells |
| Thrombopoietin | Principal regulator of megakaryocyte and platelet production |
| G-CSF, M-CSF, and interleukin 5 | Favor neutrophil, monocyte, and eosinophil production, respectively |
| Interleukin 7 and interleukin 15 | Support lymphoid development: interleukin 7 for B and T cell precursors, interleukin 15 for NK cells |
Growth-factor effects overlap, and their actions depend on receptor expression and the cell's stage of commitment. A factor associated with one lineage can also support an earlier multipotent population. BFU-E depends less on erythropoietin than CFU-E does, and it still needs some erythropoietin signal.4
Megakaryocytes follow a different size pattern. Erythroid and granulocytic precursors generally become smaller as their chromatin condenses. Megakaryocytes grow into large, rare marrow cells under thrombopoietin/MPL signaling. Their endomitotic cell cycle replicates DNA without completed cytokinesis, producing a multilobated polyploid nucleus. Maturation adds α-granules, dense granules, and a demarcation membrane system that supplies membrane for platelet formation. Mature cells extend proplatelets in the marrow sinusoidal niche and release thousands of platelets during their life span. Bone marrow is the primary steady-state site of this process. The hemostasis lessons cover platelet activation and primary hemostasis in detail.1,5
Erythroid maturation
BFU-E and CFU-E are colony-assay designations. They have no distinctive appearance under routine light microscopy, so you will not identify them on a film. The pronormoblast is the first morphologically recognizable erythroid precursor. From that point forward, cell and nuclear size decrease, chromatin condenses, nucleoli disappear, and cytoplasm changes from RNA-rich blue to hemoglobin-rich pink. The cell expels its nucleus after the orthochromic stage. Residual ribosomal RNA remains in the reticulocyte and produces a reticular network with a supravital stain.1,4
Scroll sideways to see all columns
| Normoblastic name used in the United States | Approximate diameter | Nuclear change | Cytoplasmic change | Defining event |
|---|---|---|---|---|
| Pronormoblast | 17–24 µm | Fine chromatin, 1 or more nucleoli, high nucleus-to-cytoplasm ratio | Deep blue | First recognizable erythroid precursor |
| Basophilic normoblast | 10–17 µm | Coarser chromatin; nucleoli disappear in later cells | Deep blue from abundant RNA | Hemoglobin synthesis has begun |
| Polychromatic normoblast | 10–15 µm | Coarse, condensed chromatin | Gray-blue mixture of RNA and hemoglobin | Final mitotic stage |
| Orthochromic normoblast | 8–12 µm | Small, pyknotic nucleus | Mostly pink from hemoglobin | Nuclear extrusion |
| Reticulocyte | Slightly larger than a mature erythrocyte | Anucleate | Slight blue cast on Wright stain; reticulum on supravital stain | Final RNA and organelle removal |
| Mature erythrocyte | 6.7–7.8 µm | Anucleate | Pink with central pallor | Deformable circulating oxygen carrier |
These dimensions are approximate and are given as a guide to recognition. Specimen preparation and measurement method affect the apparent size.6
Two other systems name the same sequence. Rubriblastic terms run rubriblast, prorubricyte, rubricyte, and metarubricyte. Erythroblastic terms use proerythroblast followed by basophilic, polychromatic, and orthochromatic erythroblast. Use one naming system consistently in your laboratory, so reports and training read the same way.
The nucleus-to-cytoplasm ratio is a visual estimate of relative area. A high ratio means that the nucleus occupies most of the cell. The ratio falls during erythroid maturation because nuclear contraction outpaces the decrease in cell size. Cytoplasmic color is a second, independent maturation feature. Ribosomal RNA stains blue, and hemoglobin produces the pink-orange color of a mature red cell.
Oxygen sensing and erythropoietic response
Renal peritubular interstitial fibroblast-like cells produce most erythropoietin after birth. Reduced tissue oxygen stabilizes hypoxia-inducible factor, especially HIF-2α, which increases transcription of the erythropoietin gene. Circulating erythropoietin binds its receptor on committed erythroid progenitors and activates JAK2 and STAT5 signaling. This signal promotes survival of CFU-E cells and early erythroblasts and supports proliferation and differentiation.7
The response follows this sequence:
- Tissue hypoxia increases renal erythropoietin production.
- Erythropoietin preserves and expands responsive erythroid progenitors.
- Marrow releases reticulocytes earlier and increases total red-cell output.
- Reticulocytosis and polychromasia become visible as the response reaches peripheral blood.
- Restored oxygen delivery lowers the erythropoietin stimulus.
Erythroblasts also release erythroferrone during an erythropoietic response. Erythroferrone lowers hepcidin, which increases iron availability for hemoglobin synthesis. An effective marrow response therefore requires adequate accessible iron even when erythropoietin signaling is strong.7
Reticulocytes ordinarily finish maturation over about 1 to 2 days after enucleation, including approximately 1 day in peripheral blood. Strong stimulation releases larger, RNA-rich stress reticulocytes. A reticulocyte percentage can therefore appear high even when the absolute output is inadequate for the degree of anemia. To judge the marrow response in an anemia workup, use the absolute reticulocyte count and, when needed, a production correction.
Erythrocyte clearance and iron recycling
A mature erythrocyte circulates for about 120 days. It cannot replace damaged proteins through new protein synthesis, so cumulative metabolic, oxidative, membrane, and mechanical changes reduce its deformability. Macrophages in the spleen, liver, and marrow remove aged or damaged cells and recover their iron. The signals that mark an individual cell for removal are not fully defined.3
Scroll sideways to see all columns
| Route | Site and mechanism | Expected laboratory consequences when accelerated |
|---|---|---|
| Extravascular hemolysis | Macrophages phagocytose poorly deformable or antibody-coated erythrocytes, chiefly in spleen and liver | Increased indirect bilirubin and lactate dehydrogenase; reticulocytosis when marrow reserve is adequate; splenomegaly can occur |
| Intravascular hemolysis | Erythrocytes rupture within the circulation and release hemoglobin into plasma | Decreased haptoglobin, hemoglobinemia, hemoglobinuria, increased lactate dehydrogenase, and possible hemosiderinuria with ongoing loss |
Plasma haptoglobin binds cell-free hemoglobin for uptake chiefly by CD163-positive macrophages. Hemopexin binds free heme for receptor-mediated uptake by hepatocytes and macrophages. Significant intravascular hemolysis can exceed these scavenging systems, which explains the fall in haptoglobin and appearance of hemoglobin in plasma and urine.8
Howell-Jolly bodies on a blood film reflect splenic function. Splenic macrophages perform pitting, removing inclusions such as Howell-Jolly bodies and returning the erythrocyte to the circulation. Persistent Howell-Jolly bodies therefore suggest reduced splenic filtration.
Macrophage heme oxygenase opens the heme ring to form biliverdin and releases iron and carbon monoxide. Biliverdin reductase forms unconjugated bilirubin, which travels bound to albumin to the liver. Hepatocyte UGT1A1 conjugates bilirubin for biliary excretion. Macrophage ferroportin exports recovered iron, and transferrin carries it back to developing erythroblasts. Erythrocyte recycling supplies far more daily iron to marrow than intestinal absorption.1,3,9
Membrane, metabolism, and deformability
The erythrocyte's thin biconcave profile provides excess surface area for its volume. Its flexible membrane skeleton allows an approximately 7 to 8 µm cell to pass through narrow capillaries and splenic slits. Deformability depends on three linked properties: surface-area-to-volume ratio, internal viscosity set largely by hemoglobin concentration, and the mechanical integrity of the membrane skeleton.10
The lipid bilayer connects to a spectrin-actin network through two major attachment systems. The ankyrin complex includes band 3, protein 4.2, ankyrin, and β-spectrin. The junctional complex includes spectrin, actin, protein 4.1R, and several membrane partners. Defects that weaken bilayer-to-skeleton attachments promote membrane loss and spherocytes. Defects that weaken the spectrin network impair mechanical stability and promote elliptocytes or fragmentation.10
Mature erythrocytes lack mitochondria and depend on cytosolic glucose metabolism:
Scroll sideways to see all columns
| Pathway or system | Main product or action | Laboratory consequence of failure |
|---|---|---|
| Embden-Meyerhof glycolysis | ATP and NADH | ATP depletion impairs cation pumps and membrane flexibility; low NADH impairs methemoglobin reduction |
| Pentose phosphate pathway | NADPH | Reduced antioxidant defense permits hemoglobin denaturation and Heinz body formation |
| Rapoport-Luebering shunt | 2,3-bisphosphoglycerate | Altered 2,3-BPG changes hemoglobin oxygen affinity |
| Band 3 anion exchange | Rapid chloride-bicarbonate exchange | Supports carbon dioxide carriage and acid-base balance |
ATP-dependent pumps maintain cell volume and low cytosolic calcium. Net cation gain draws water into the cell and reduces the surface-area-to-volume reserve. Net potassium and water loss dehydrates the cell and raises internal viscosity. Either direction can reduce deformability and shorten survival.
Hemoglobin gas transport
Hemoglobin A contains two α and two β chains (α2β2), hemoglobin A2 contains two α and two δ chains (α2δ2), and fetal hemoglobin contains two α and two γ chains (α2γ2). Hb H is a tetramer of β chains (β4) that can form when α-chain production is markedly reduced. Hemoglobin analysis identifies which fractions are present and measures how much of each. To interpret the measured proportions, you also need the patient's age, transfusion history, and the separation method.11
Each hemoglobin molecule contains four globin chains and four hemes. Ferrous iron in each heme binds one oxygen molecule reversibly. Interaction among the subunits makes binding cooperative, producing the sigmoid oxygen dissociation curve. P50 is the PO2 at which hemoglobin is 50% saturated and is about 26 to 27 mm Hg for normal adult blood under standard conditions. A lower P50 indicates higher oxygen affinity. A higher P50 indicates lower affinity and easier tissue unloading.12
Scroll sideways to see all columns
| Curve change | Common causes | Functional effect |
|---|---|---|
| Left shift, lower P50 | Lower 2,3-BPG, alkalosis, lower PCO2, lower temperature, fetal hemoglobin, high-affinity variants | Greater affinity and reduced oxygen release at a given PO2 |
| Right shift, higher P50 | Higher 2,3-BPG, acidosis, higher PCO2, higher temperature, low-affinity variants | Lower affinity and greater oxygen release at a given PO2 |
Deoxygenated hemoglobin favors the tense state and binds 2,3-BPG between its β chains. Oxygenation shifts hemoglobin toward the relaxed state and displaces 2,3-BPG. The pH effect is the Bohr effect: hydrogen ion binding in metabolically active tissue lowers oxygen affinity and promotes unloading. Fetal hemoglobin binds 2,3-BPG less strongly and therefore has a higher oxygen affinity than adult hemoglobin.12
Most carbon dioxide produced by tissues is carried as bicarbonate. Carbon dioxide enters the erythrocyte, where carbonic anhydrase rapidly forms carbonic acid, which dissociates into hydrogen ion and bicarbonate. Deoxygenated hemoglobin buffers the hydrogen ion. Band 3 exchanges intracellular bicarbonate for plasma chloride, producing the chloride shift. The sequence reverses in pulmonary capillaries. Oxygenation lowers hemoglobin's capacity to bind hydrogen ions and carbon dioxide, the Haldane effect, and promotes carbon dioxide release into alveolar gas for exhalation.13
The Erythrocyte Physiology and the Storage Lesion lesson applies membrane metabolism and oxygen-affinity principles to refrigerated blood components.
Practice
References
- Keohane EM, Preston MM, Mirza KM, Walenga JM, eds. Rodak's Hematology: Clinical Principles and Applications. 7th ed. Elsevier; 2025. Accessed August 28, 2026. Back to text
- Vink CS, Mariani SA, Dzierzak E. Embryonic origins of the hematopoietic system: hierarchies and heterogeneity. HemaSphere. 2022;6(6):e737. doi:10.1097/HS9.0000000000000737 Back to text
- Borges MD, Sesti-Costa R. Macrophages: key players in erythrocyte turnover. Hematol Transfus Cell Ther. 2022;44(4):574-581. doi:10.1016/j.htct.2022.07.002 Back to text
- Schippel N, Sharma S. Dynamics of human hematopoietic stem and progenitor cell differentiation to the erythroid lineage. Exp Hematol. 2023;123:1-17. doi:10.1016/j.exphem.2023.05.001 Back to text
- Asquith NL, Carminita E, Camacho V, et al. The bone marrow is the primary site of thrombopoiesis. Blood. 2024;143(3):272-278. doi:10.1182/blood.2023020895 Back to text
- College of American Pathologists. 2026 Hematology, Clinical Microscopy, and Body Fluids Glossary. 2026:7,31-32. Accessed September 7, 2026. Back to text
- Bhoopalan SV, Huang LJ, Weiss MJ. Erythropoietin regulation of red blood cell production: from bench to bedside and back. F1000Res. 2020;9:1153. doi:10.12688/f1000research.26648.1 Back to text
- Schaer DJ, Vinchi F, Ingoglia G, Tolosano E, Buehler PW. Haptoglobin, hemopexin, and related defense pathways: basic science, clinical perspectives, and drug development. Front Physiol. 2014;5:415. doi:10.3389/fphys.2014.00415 Back to text
- Korolnek T, Hamza I. Macrophages and iron trafficking at the birth and death of red cells. Blood. 2015;125(19):2893-2897. doi:10.1182/blood-2014-12-567776 Back to text
- Mohandas N, Gallagher PG. Red cell membrane: past, present, and future. Blood. 2008;112(10):3939-3948. doi:10.1182/blood-2008-07-161166 Back to text
- Tamary H, Greenberg-Kushnir N, Dgany O. Alpha-thalassemia. GeneReviews. Updated April 23, 2026. Accessed September 7, 2026. Back to text
- Jaafar LS, Kourie CMR, El-Mallah CA, Obeid O. 2,3-Diphosphoglycerate: the forgotten metabolic regulator of oxygen affinity. Br J Nutr. 2025;134(10):803-815. doi:10.1017/S0007114525105345 Back to text
- Jennings ML. Cell physiology and molecular mechanism of anion transport by erythrocyte band 3/AE1. Am J Physiol Cell Physiol. 2021;321(6):C1028-C1059. doi:10.1152/ajpcell.00275.2021 Back to text